home / stock / mbio / mbio news

MBIO News and Press, Mustang Bio Inc. From 11/12/19

Stock Information
Company Name: Mustang Bio Inc.
Stock Symbol: MBIO
Market: NASDAQ
Website: mustangbio.com
Menu
MBIO MBIO Quote MBIO Short MBIO News MBIO Articles MBIO Message Board
Get MBIO Alerts

News, Short Squeeze, Breakout and More Instantly...
MBIO - Mustang Bio EPS beats by $0.01

Mustang Bio (NASDAQ: MBIO ): Q3 GAAP EPS of -$0.25 beats by $0.01 . More news on: Mustang Bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

MBIO - Mustang Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumor...

MBIO - Mustang Bio Announces MB-107 Lentiviral Gene Therapy and MB-106 CD20-Targeted CAR T Data Selected for Presentations at 61st American Society of Hematology Annual Meeting

St. Jude Children’s Research Hospital and the National Institutes of Health to present updated MB-107 clinical data for the treatment of X-linked severe combined immunodeficiency Fred Hutchinson Cancer Research Center to present overview of ongoing MB-106 Phase 1/2 clinical tria...

MBIO - Mustang Bio Announces Dosing of First Participant in Phase 1 Clinical Trial of MB-108 (Oncolytic Virus C134) to Treat Glioblastoma

NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumor...
MBIO - Mustang Bio Announces City of Hope Receives $4.1 Million in Grant Awards for Recently Opened First-of-Its-Kind Clinical Trial for Patients with Recurrent Malignant Glioma

NEW YORK, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumor...

MBIO - Fortress Biotech Preferred: Another Look At This Speculative 11.5% Yielder With More Cash Than Debt

Fortress Biotech ( FBIO ) has made significant progress since my 11/24/2018 article on the Fortress Biotech Inc. 9.375% Cum Conv Perp Red Pfd Registered Shs Series ( FBIOP ). Although FBIOP remains a speculative issue, it has appreciated in price from $17.58 to $20.00 since my last artic...

MBIO - Mustang Bio to Participate in October 2019 Investor Conferences

NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumo...
MBIO - Mustang Bio Announces Phase 1 Clinical Trial Evaluating MB-105 for Prostate Stem Cell Antigen-Positive Castration-Resistant Prostate Cancer Enrolling Patients at City of Hope

NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumo...

MBIO - Mustang Bio to Present at Scientific Conferences in September 2019

NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumo...

MBIO - Mustang Bio Adopts CryoStor® Freeze Media and evo® Cold Chain System for Cell and Gene Therapy Manufacturing and Distribution

BOTHELL, Wash. , Sept. 3, 2019 /PRNewswire/ --   BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that Mustang Bio, Inc. (NASDAQ: MBIO), a clinical-stage b...
Previous 10 Next 10